Longitudinal changes in dehydroepiandrosterone concentrations in men and women

doi:10.1016/S0022-2143(98)90181-0

Journal of Laboratory and Clinical Medicine

Volume 131, Issue 4, April 1998, Pages 316-323

https://doi.org/10.1016/S0022-2143(98)90181-0 Get rights and content

Abstract

Dehydroepiandrosterone, an adrenal steroid, has many purported roles in the body and has been used as an oral supplement in the treatment of various illnesses. Because little is known about normal changes over time in dehydroepiandrosterone concentrations, we studied the 5-year change in plasma dehydroepiandrosterone concentrations in 614 free-living adults. Two hundred seventy-three males and 341 females had dehydroepiandrosterone and dehydroepiandrosterone sulfate concentrations measured in 1989 and 1994. Demographic data were also obtained. Dehydroepiandrosterone concentrations differed significantly by sex and 5-year age group. The average decline in dehydroepiandrosterone was 5.6%/year, and the rate of decline was directly related to age but not to sex, measures of adiposity, or serum glucose. Dehydroepiandrosterone sulfate concentrations differed significantly by sex and age group. The average decline in the sulfated hormone was 2.0%/year and was not related to age, sex, measures of adiposity, or serum glucose. Knowledge of the natural course of age-related changes in dehydroepiandrosterone and dehydroepiandrosterone sulfate concentrations is essential to our understanding of the relationship of dehydroepiandrosterone to chronic diseases.

References (41)

AW Meikle et al.
Adrenal androgen secretion and biologic effects
Endocrinol Metab Clin North Am
(1991)
AW Meikle et al.
The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells
J Steroid Biochem Mol Biol
(1992)
E Roberts et al.
Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice
Brain Res
(1987)
GB Gordon et al.
Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone
Adv Enzyme Regul
(1987)
DM Herrington et al.
Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography
J Am Coll Cardiol
(1990)
F Leblhuber et al.
Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea
J Neurol Sci
(1995)
JE Buster et al.
Postmenopausal steroid replacement with micronized dehydroepiandrosterone: Preliminary oral bioavailability and dose proportionality studies
Am J Obstet Gynecol
(1992)
SJ Bowlin et al.
Validity of cardiovascular disease risk factors assessed by telephone survey: the behavioral risk factor survey
J Clin Epidemiol
(1993)
PA Marks et al.
Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids
RS Rosenfeld et al.
Metabolism and interconversion of dehydroepiandrosterone and dehydroepiandrosterone sulfate
J Clin Endocrinol Metab
(1972)

G Van den Berghe et al.

Dehydroepiandrosterone sulphate in critical illness: effect of dopamine

Clin Endocrinol

(1995)

JM Whitcomb et al.

Dehydroepiandrosterone and 16α-Br-epiandrosterone inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of superoxide radical production by human polymorphonuclear leukocytes

Carcinogenesis

(1985)

MP Cleary

The antiobesity effect of dehydroepiandrosterone in rats

AG Schwartz et al.

1983 Dehydroepiandrosterone: An anti-obesity and anticarcinogenic agent

Commun Res Breast Disease

(1983)

GB Gordon et al.

Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer

Cancer Research

(1990)

E Barrett-Connor et al.

A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease

N Engl J Med

(1986)

T Yanase et al.

Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia

Endocr J

(1996)

F Leblhuber et al.

Antiglucocorticoid effects of DHEA-S in Alzheimer's disease

Am J Psychiatry

(1992)

OM Wolkowitz et al.

Antiglucocorticoid effects of DHEA-S in Alzheimer's disease

Am J Psychiatry

(1992)

JE Nestler et al.

Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men

J Clin Endocrinol Metab

(1988)

Cited by (75)

What matters in aging is signaling for responsiveness
2023, Pharmacology and Therapeutics
Biological responsiveness refers to the capacity of living organisms to adapt to changes in both their internal and external environments through physiological and behavioral mechanisms. One of the prominent aspects of aging is the decline in this responsiveness, which can lead to a deterioration in the processes required for maintenance, survival, and growth. The vital link between physiological responsiveness and the essential life processes lies within the signaling systems. To devise effective strategies for controlling the aging process, a comprehensive reevaluation of this connecting loop is imperative.
This review aims to explore the impact of aging on signaling systems responsible for responsiveness and introduce a novel perspective on intervening in the aging process by restoring the compromised responsiveness. These innovative mechanistic approaches for modulating altered responsiveness hold the potential to illuminate the development of action plans aimed at controlling the aging process and treating age-related disorders.
Gender differences in susceptibility to schizophrenia: Potential implication of neurosteroids
2017, Psychoneuroendocrinology
Citation Excerpt :
Neurosteroids either come naturally from steroid-producing endocrine glands or are synthesized from precursors of sterol in the central nervous system (CNS) de novo (Baulieu and Robel, 1998). The most abundant neurosteroids secreted by the adrenal cortex in humans are dehydroepiandrosterone (DHEA) and its sulfate ester DHEA-S (Nafziger et al., 1998), which behave as the precursors of the sex hormones androgen and estrogen (Ritsner et al., 2005). The peripheral levels of DHEA/DHEA-S rise during puberty and achieve peak values between the early twenties and thirties (Kushnir et al., 2010) and then decrease over time to 10% to 20% of said peak values between 80 and 90 years old (Baulieu, 1996).
Past research has indicated gender differences in the clinical characteristics and course of schizophrenia. In this study, we investigated whether gender differences in the manifestation of schizophrenia are correlated with neurosteroids, including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and pregnenolone. We further explored the potential relationship between the aforementioned neurosteroids and psychopathology. We recruited 65 schizophrenic patients (36 males and 29 females) and 103 healthy control subjects (47 males and 56 females) and obtained blood samples from the subjects in the morning while in a fasting state to determine the serum levels of DHEA, DHEA-S, and pregnenolone. The psychopathology and mood symptoms of patients with schizophrenia were evaluated using the Positive and Negative Syndrome Scale (PANSS) and 17-item Hamilton Depression Rating Scale, respectively. Compared to the male control subjects, male patients with schizophrenia had significantly lower serum levels of DHEA and pregnenolone. In males with schizophrenia, the serum levels of DHEA and DHEA-S were associated with the age of onset and the duration of illness, while pregnenolone levels were associated with general symptoms of the PANSS. However, none of the neurosteroid levels were different between the female patients with schizophrenia and the female controls, and no significant correlation between neurosteroid levels and psychopathology evaluations was found among the schizophrenic females. Neurosteroids, including DHEA, DHEA-S, and pregnenolone, are involved in the pathophysiology of schizophrenia in male patients, but not in female ones. Therefore, our findings suggest that neurosteroids may be associated with gender differences in susceptibility to schizophrenia.
Serum dehydroepiandrosterone sulfate in assessing the integrity of the hypothalamic-pituitary-adrenal axis
2017, Journal of Clinical and Translational Endocrinology
To evaluate the relationship between age- and gender-adjusted dehydroepiandrosterone sulfate (DHEA-S) levels and low-dose adrenocorticotropic hormone (ACTH) stimulation in assessing the integrity of the hypothalamic-pituitary-adrenal (HPA) axis, in patients who were at risk of HPA insufficiency, including those currently being treated with glucocorticoids.
Forty-six participants with a suspicion of secondary adrenal insufficiency were recruited from the Diabetes and Endocrinology Clinic at Ramathibodi Hospital, Mahidol University, Bangkok. Low-dose (1 μg) ACTH stimulation was performed in every participants, and serum DHEA-S was measured at baseline before ACTH injection.
Individuals with normal age- and gender-specific DHEA-S levels had baseline serum cortisol and peak cortisol levels higher than those with reduced DHEA-S. Normal age- and gender-specific DHEA-S levels predicted intact HPA function with a sensitivity of 87.1%, a specificity of 86.7%, a positive predictive value of 93.1%, and a negative predictive value of 76.5%. To account for the age and gender dependency of DHEA-S, the DHEA-S ratio was calculated by measured DHEA-S divided by the lower limit of the respective reference range for all participants. A DHEA-S ratio of more than 1.78 had 100% sensitivity regarding intact HPA function. Area under the receiver operating characteristic [ROC] curve was 0.920. (95% CI, 0.844–0.997).
Normal age- and gender-specific DHEA-S level or a DHEA-S ratio of more than 1.78 are valuable markers of HPA integrity. Serum DHEA-S may be a candidate for a less costly approach where ACTH stimulation is unavailable.
Role of steroid sulfatase in steroid homeostasis and characterization of the sulfated steroid pathway: Evidence from steroid sulfatase deficiency
2016, Molecular and Cellular Endocrinology
The impact of steroid sulfatase (STS) activity in the circulating levels of both sulfated and unconjugated steroids is only partially known. In addition, the sulfated steroid pathway, a parallel pathway to the one for unconjugated steroids, which uses the same enzymes, has never been characterized in detail before. Patients with steroid sulfatase deficiency (STSD) are unable to enzymatically convert sulfated steroids into their unconjugated forms, and are a good model to elucidate how STS affects steroid biosynthesis and to study the metabolism of sulfated steroids. We quantified unconjugated and sulfated steroids in STSD serum, and compared these results with data obtained from serum of healthy controls. Most sulfated steroids were increased in STSD. However, androstenediol-3-sulfate and epiandrosterone sulfate showed similar levels in both groups, and the concentrations of androsterone sulfate were notably lower. Hydroxylated forms of DHEAS and of pregnenolone sulfate were found to be increased in STSD, suggesting a mechanism to improve the excretion of sulfated steroids. STSD testosterone concentrations were normal, but cholesterol and DHEA were significantly decreased. Additionally, serum bile acids were three-fold higher in STSD. Correlations between concentrations of steroids in each group indicate that 17α-hydroxy-pregnenolone-3-sulfate in men is mainly biosynthesized from the precursor pregnenolone sulfate and androstenediol-3-sulfate from DHEAS. These findings confirm the coexistence of two steroidogenic pathways: one for unconjugated steroids and another one for sulfated steroids. Each pathway is responsible for the synthesis of specific steroids. The equal levels of testosterone, and the reduced level of unconjugated precursors in STSD, support that testosterone is primarily synthesized from sulfated steroids. In consequence, testosterone synthesis in STSD relies on an enzyme with sulfatase activity other than STS. This study reveals that STS is a key player of steroid biosynthesis regulating the availability of circulating cholesterol.
The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia
2011, Neuroscience
Neurosteroids such as dehydroepiandrosterone (DHEA), pregnenolone (PREG), and their sulfates (DHEAS and PREGS) display multiple effects on the central nervous system. Specifically, neurosteroids have various functions associated with neuroprotection, response to stress, mood regulation, and cognitive performance. In addition, neurosteroid levels are altered in stress-related neuropsychiatric disorders. This review focuses on the alterations of these neurosteroids in schizophrenia and on their association with clinical and neurocognitive manifestations. As described henceforth, findings from clinical studies have revealed that PREG, DHEA, and their sulfates might be involved in the pathophysiology of schizophrenia, and in some of its manifestations. Clinical trials for the evaluation of these neurosteroids face challenges in terms of experimental design, dosing strategy, data analysis, and interpretation. The review concludes with a list of suggested topics for future research.
This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain.
Pharmacology and immune modulating properties of 5-androstene-3β, 7β,17β-triol, a DHEA metabolite in the human metabolome
2011, Journal of Steroid Biochemistry and Molecular Biology
Citation Excerpt :
DHEA together with its sulfate conjugate are among the most abundant steroids found in human circulation [1]. In humans age-related declines in plasma DHEA coincide with a heightened pro-inflammatory status [2,3]. DHEA has activity in certain in vitro systems [4], and is remarkably effective as a chemoprotectant and anti-inflammatory agent in rodent models [4–9].
Androst-5-ene-3β,7β,17β-triol (βAET) is an anti-inflammatory metabolite of DHEA that is found naturally in humans, but in rodents only after exogenous DHEA administration. Unlike DHEA, C-7-oxidized DHEA metabolites cannot be metabolized into potent androgens or estrogens, and are not peroxisome proliferators in rodents. The objective of our current studies was to characterize the pharmacology of βAET to enable clinical trials in humans. The pharmacology of βAET was characterized by pharmacokinetics, drug metabolism, nuclear hormone receptor interactions, androgenicity, estrogenicity, and systemic toxicity studies. βAET's acute anti-inflammatory activity and immune modulating characteristics were measured in vitro in RAW264.7 cells and in vivo in murine models with parenteral administration. βAET was rapidly metabolized and cleared from circulation in mice and monkeys. βAET was weakly androgenic and estrogenic in immature rodents, but not bound by androgen, estrogen, progesterone, or glucocorticoid nuclear hormone receptors. βAET did not induce peroxisome proliferation, nor was it systemically toxic or trophic for sex hormone responsive tissues in mature rats and monkeys. βAET significantly attenuated acute inflammation both in vitro and in vivo, augmented immune responses in adult mice, and reversed immune senescence in aged mice. βAET may contribute to the anti-inflammatory activity in rodents attributed to DHEA. Unlike DHEA, βAET's anti-inflammatory activity cannot be ascribed to activation of PPARs, androgen, or estrogen nuclear hormone receptors. Exogenous βAET is unlikely to produce untoward toxicity or hormonal perturbations in humans.

View all citing articles on Scopus

View full text

Original articleLongitudinal changes in dehydroepiandrosterone concentrations in men and women

Abstract

Endocrinol Metab Clin North Am

J Steroid Biochem Mol Biol

Brain Res

Adv Enzyme Regul

J Am Coll Cardiol

J Neurol Sci

Am J Obstet Gynecol

J Clin Epidemiol

Inhibition of mammalian glucose-6-phosphate dehydrogenase by steroids

Metabolism and interconversion of dehydroepiandrosterone and dehydroepiandrosterone sulfate

J Clin Endocrinol Metab

Dehydroepiandrosterone sulphate in critical illness: effect of dopamine

Clin Endocrinol

Dehydroepiandrosterone and 16α-Br-epiandrosterone inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of superoxide radical production by human polymorphonuclear leukocytes

Carcinogenesis

The antiobesity effect of dehydroepiandrosterone in rats

1983 Dehydroepiandrosterone: An anti-obesity and anticarcinogenic agent

Commun Res Breast Disease

Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer

Cancer Research

A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease

N Engl J Med

Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia

Endocr J

Antiglucocorticoid effects of DHEA-S in Alzheimer's disease

Am J Psychiatry

Antiglucocorticoid effects of DHEA-S in Alzheimer's disease

Am J Psychiatry

Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men

J Clin Endocrinol Metab

Original article
Longitudinal changes in dehydroepiandrosterone concentrations in men and women